Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania

Pilot and Feasibility Studies - Tập 9 Số 1
Stellah Mpagama1, Happiness C Mvungi1, Peter M. Mbelele1, Hadija Semvua2, Alphonce Liyoyo1, Kristen Petros de Guex3, Derek Sloan4, Gibson Kibiki5, Martin J. Boeree6, Patrick Phillips7, Scott K Heysell3
1Kibong'oto Infectious Diseases Hospital–Sanya Juu Siha/Kilimanjaro Clinical Research Institute, Mae Street, Lomakaa Road, Siha Kilimanjaro, Tanzania
2Kilimanjaro Christian Medical University College, Moshi, Kilimanjaro, Tanzania
3Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, USA
4University of St Andrews, St Andrews, UK
5Africa Research Excellence Fund, London, UK
6Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, the Netherlands
7UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, USA

Tóm tắt

Abstract Background Adverse drug reactions (ADRs) frequently occur in patients using second-line anti-tuberculosis medicine for treatment of multidrug resistant tuberculosis (MDR-TB). ADRs contribute to treatment interruptions which can compromise treatment response and risk acquired drug resistance to critical newer drugs such as bedaquiline, while severe ADRs carry considerable morbidity and mortality. N-acetylcysteine (NAC) has shown promise in reducing ADRs for medications related to TB in case series or randomized controlled trials in other medical conditions, yet evidence is lacking in MDR-TB patients. TB endemic settings have limited capacity to conduct clinical trials. We designed a proof-of-concept clinical trial primarily to explore the preliminary evidence on the protective effect of NAC among people treated for MDR-TB with second-line anti-TB medications. Methods This is a proof-of-concept randomized open label clinical trial with 3 treatment arms including a control arm, an interventional arm of NAC 900 mg daily, and an interventional arm of NAC 900 mg twice-daily administered during the intensive phase of MDR-TB treatment. Patients initiating MDR-TB treatment will be enrolled at Kibong’oto National Center of Excellence for MDR-TB in the Kilimanjaro region of Tanzania. The minimum anticipated sample size is 66; with 22 participants in each arm. ADR monitoring will be performed at baseline and daily follow-up over 24 weeks including blood and urine specimen collection for hepatic and renal function and electrolyte abnormalities, and electrocardiogram. Sputum will be collected at baseline and monthly thereafter and cultured for mycobacteria as well as assayed for other molecular targets of Mycobacterium tuberculosis. Adverse drug events will be analysed over time using mixed effect models. Mean differences between arms in change of the ADRs from baseline (with 95% confidence intervals) will be derived from the fitted model. Discussion Given that NAC promotes synthesis of glutathione, an intracellular antioxidant that combats the impact of oxidative stress, it may protect against medication induced oxidative damage in organs such as liver, pancreas, kidney, and cells of the immune system. This randomized controlled trial will determine if NAC leads to fewer ADRs, and if this protection is dose dependent. Fewer ADRs among patients treated with MDR-TB may significantly improve treatment outcomes for multidrug regimens that necessitate prolonged treatment durations. Conduct of this trial will set the needed infrastructure for clinical trials. Trial registration PACTR202007736854169 Registered 03 July 2020

Từ khóa


Tài liệu tham khảo

WHO: Global Tuberculosis Report. In., vol. WHO/HTM/TB/2016.13; 2016.

WHO: Global Tuberculosis Report. 2019.

Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, Hamlet A, Smith JA, Winskill P, Verity R et al: Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health 2020;8(9):e1132–e1141.

Brigden G, Nyang’wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR Jr, Mitnick CD, Nuermberger E, McIlleron H, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014;92(1):68–74.

Mpagama SG, Houpt ER, Stroup S, Kumburu H, Gratz J, Kibiki GS, Heysell SK. Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. BMC Infect Dis. 2013;13:432.

WHO. Guidelines for the programmatic management of drug-resistant tuberculosis Emergency Update. 2008.

Ahmad N, Ahuja SD, Akkerman OW, Alffenaar J-WC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821–34.

WHO. WHO Consolidated guidelines on drug resistant tuberculosis treatment. 2019.

Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019;380(13):1201–13.

Mpagama SG, Heysell SK, Ndusilo ND, Kumburu HH, Lekule IA, Kisonga RM, Gratz J, Boeree MJ, Houpt ER, Kibiki GS. Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania. PLoS ONE. 2013;8(5):e62034.

Malik AA, Fuad J, Siddiqui S, Amanullah F, Jaswal M, Barry Z, Jabeen F, Fatima R, Yuen CM, Salahuddin N, et al. Tuberculosis preventive therapy for individuals exposed to drug-resistant tuberculosis: feasibility and safety of a community-based delivery of fluoroquinolone-containing preventive regimen. Clin Infect Dis. 2020;70(9):1958–65.

Mbuagbaw L: Review of available evidence on the use of bedaquiline for the treatment of multidrug resistant tuberculosis: data analysis report. Prepared for The World Health Organization. McMaster University: Health Research Methods, Evidence and Impact 2017

Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2016;15(1):41.

Hwang TJ, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K, Nunn P, Jaramillo E, Keshavjee S, Wares DF. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open. 2014;4(1): e004143.

Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis. 2018;18(5):536–44.

Winterbourn C, Metodiewa D. Reactivity of biologically important thiol compounds with superoxide and hydroen peroxide. Free Radical Biol Med. 1999;27(3/4):322–8.

Pompella A, Visvikis A, Paolicchi A, Tata VD, Casini AF. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol. 2003;66(8):1499–503.

ElbiniDhouib I, Jallouli M, Annabi A, Gharbi N, Elfazaa S, Lasram MM. A minireview on N-acetylcysteine: an old drug with new approaches. Life Sci. 2016;151:359–63.

Ershad M, Naji A, Vearrier D: N Acetylcysteine NCBI Bookshelf A service of the National Library of Medicine, National Institutes of Health: StatPearls Publishing LLC 2020

Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR, Velayati AA. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol. 2010;22(10):1235–8.

Farazi A, Sofian M, Jabbariasl M. Efficacy of N-Acetylcysteine on Prevention of Antituberculosis Drug-Induced Hepatotoxicity. World J Med Sci. 2015;12(4):413–8.

Kranzer K, Elamin WF, Cox H, Seddon JA, Ford N, Drobniewski F. A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. Thorax. 2015;70(11):1070–7.

Raviglione M: Vision and proposed framework for a Post-2015 TB Elimination Strategy and Targets; Consultation on "Elimination the catastrophic economic burden of TB" Universal Health Coverage and Social Protection Opportnities In: 2013; Sao Paulo, Brazil, 29 April - 1 May 2013; 2013.

Nyaki FS, Taksdal M, Mbuya AW, Sariko M, Lekule IA, Kisonga RM, Kibiki GS, Mmbaga BT, Heysell SK, Mpagama SG. Predictors of Nutritional Status in Patients Treated for Multidrug-Resistant Tuberculosis at a Referral Hospital in Tanzania. J Clin Infect Dis Pract. 2016;01(02):115.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39–49.

Heysell SK, Mpagama SG, Ogarkov OB, Conaway M, Ahmed S, Zhdanova S, Pholwat S, Alshaer MH, Chongolo AM, Mujaga B et al: Pharmacokinetic-pharmacodynamic determinants of clinical outcomes for rifampin-resistant tuberculosis: a multi-site prospective cohort study. Clin Infect Dis 2022;76(3):497–505.

Horowitz J, Henry C, Syrjanen M, Louis W, Fish D, Smith T, Anman E. Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris. Circulation. 1988;77(4):787–94.

Ignarro LJ, Gruetter CS. Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite possible involvement of S-nitrosothiols. Biochimica et Biophysica Acta BBA General Subjects. 1980;631(2):221–31.

Barrios VAC, Navarro-Cid JVL, Ruilope L. N acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients. Blood Pressure. 2009;11(4):235–9.

Boesgaard S, Aldershvile J, Poulsen HE, Christensen S, Dige-Petersen H, Giese J. N-Acetylcysteine inhibits angiotensin converting enzyme in vivo. J Pharmacol Exper Theraeup. 1993;265(3):1239–44.

Costa-Campos L, Herrmann AP, Pilz LK, Michels M, Noetzold G, Elisabetsky E. Interactive effects of N-acetylcysteine and antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:125–30.

Zareifopoulos N, Panayiotakopoulos G. Neuropsychiatric effects of antimicrobial agents. Clin Drug Investig. 2017;37(5):423–37.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE et al: High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2016;17(1):39–49.

Ltd SE: Power calculator for continuous outcome superiority trial. . In. Edited by 2016]. OAfhwscpc-sAWD; 2012.

Zhang Y, Wu S, Xia Y, Wang N, Zhou L, Wang J, Fang R, Sun F, Chen M, Zhan S. Adverse Events associated with treatment of multidrug-resistant tuberculosis in China: an ambispective cohort study. Med Sci Monit. 2017;23:2348–56.

Cheng S-L: Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. In: 102 Tuberculosis. 2016.

Jeeraaumponwat T: N-acetylcysteine and mortality in hospitalized pulmonary tuberculosis infection. In: Tuberculosis. 2019.

Campochiaro PA, Iftikhar M, Hafiz G, Akhlaq A, Tsai G, Wehling D, Lu L, Wall GM, Singh MS, Kong X. Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial. J Clin Invest. 2020;130(3):1527–41.

Mullins ME, Vitkovitsky IV. Hemolysis and hemolytic uremic syndrome following five-fold N-acetylcysteine overdose. Clin Toxicol (Phila). 2011;49(8):755–9.

Bailey B, Blais R, Letarte A. Status epilepticus after a massive intravenous N-acetylcysteine overdose leading to intracranial hypertension and death. Ann Emerg Med. 2004;44(4):401–6.

Cassidy N, Tracey JA, Drew SA. Cardiac arrest following therapeutic administration of N-acetylcysteine for paracetamol overdose. Clin Toxicol (Phila). 2008;46(9):921.

Thông tin
Thông tin xuất bản

Pilot and Feasibility Studies

Tập 9 Số 1

Thông tin tác giả